I think we can remove the word probably. The cost of seeking registration for the new indication is trivial for a company like PFE, so the commercial opportunity must be very small indeed.
p.s. Patent protection is not the issue, evidently. Lyrica has Orange Book patents that run until Dec 2018.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”